Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments

被引：124
|
作者：
Lane, Nancy E. [1 ]
机构：
[1] Univ Calif Davis Hlth Syst, Ctr Musculoskeletal Hlth, 4625 Second Ave,Suite 2006, Sacramento, CA 95817 USA
来源：
CURRENT OSTEOPOROSIS REPORTS | 2019年 / 17卷 / 01期
关键词：
Glucocorticoids; Bone cells; Bone vascularity; Osteonecrosis; Parathyroid hormone; PARATHYROID-HORMONE; VERTEBRAL FRACTURE; BONE-DENSITY; RISEDRONATE; PREVENTION; MICE; ALENDRONATE; STRENGTH;
D O I：
10.1007/s11914-019-00498-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of this ReviewThe goal of the review is to provide an updated understanding of the pathophysiology of glucocorticoid-induced osteoporosis and treatment recommendations.Recent FindingsGlucocorticoids reduce osteoblast and osteocyte lifespan and activity and reduce the vascularity of the bone that together may explain the greater reductions in bone strength than those of bone mass. Treatments with parathyroid hormone fragments appear to reverse glucocorticoid-induced bone loss and fracture risk partially through maintaining bone vascularity and bone strength.SummaryThis review identifies how glucocorticoid anti-osteogenic and vascular effects together may reduce bone strength. It also provides guidance to clinicians on rationale treatment for glucocorticoid-induced osteoporosis.
引用
收藏
页码：1 / 7
页数：7
相关论文
共 50 条
  • [1] Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments
    Nancy E. Lane
    Current Osteoporosis Reports, 2019, 17 : 1 - 7
  • [2] Pathophysiology of glucocorticoid-induced osteoporosis
    Schnitzer, TJ
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 1999, 5 (05) : S10 - S15
  • [3] Glucocorticoid-induced osteoporosis: pathophysiology and therapy
    E. Canalis
    G. Mazziotti
    A. Giustina
    J. P. Bilezikian
    Osteoporosis International, 2007, 18 : 1319 - 1328
  • [4] Glucocorticoid-induced osteoporosis: pathophysiology and therapy
    Canalis, E.
    Mazziotti, G.
    Giustina, A.
    Bilezikian, J. P.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 (10) : 1319 - 1328
  • [5] PATHOPHYSIOLOGY, PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
    KECK, E
    AKTUELLE RHEUMATOLOGIE, 1994, 19 (02) : 64 - 69
  • [6] Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis
    Hennie G. Raterman
    Irene E. M. Bultink
    Willem F. Lems
    Drugs, 2019, 79 : 1065 - 1087
  • [7] Glucocorticoid-induced osteoporosis: Insights for the clinician
    Hayat, Shakaib
    Magrey, Marina N.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2020, 87 (07) : 417 - 426
  • [8] Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis
    Raterman, Hennie G.
    Bultink, Irene E. M.
    Lems, Willem F.
    DRUGS, 2019, 79 (10) : 1065 - 1087
  • [9] Glucocorticoid-induced osteoporosis: pathophysiological data and recent treatments
    Lafage-Proust, MH
    Boudignon, B
    Thomas, T
    JOINT BONE SPINE, 2003, 70 (02) : 109 - 118
  • [10] Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis
    Iacopo, Chiodini
    Alberto, Falchetti
    Daniela, Merlotti
    Cristina, Eller Vainicher
    Luigi, Gennari
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2020, 15 (04) : 283 - 298
12345